Featured Research

from universities, journals, and other organizations

Addition of Paclitaxel to Standard Chemotherapy Improves Outcome in Early Breast Cancer

Date:
May 27, 2008
Source:
Journal of the National Cancer Institute
Summary:
Early breast cancer patients treated with standard chemotherapy followed by paclitaxel had better disease-free survival compared with patients treated with standard therapy alone, according to the final results from a randomized phase III trial. Paclitaxel and other taxanes are among the most active agents in metastatic breast cancer. Researchers are now testing the drugs in patients with early, non-metastatic breast cancer.

Early breast cancer patients treated with standard chemotherapy followed by paclitaxel had better disease-free survival compared with patients treated with standard therapy alone, according to the final results from a randomized phase III trial.

Paclitaxel and other taxanes are among the most active agents in metastatic breast cancer. Researchers are now testing the drugs in patients with early, non-metastatic breast cancer.

In the current study, Miguel Martín, M.D., of the Spanish Breast Cancer Research Group and colleagues randomly assigned 1,246 women to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or FEC followed by weekly paclitaxel (FEC-P).

The estimated 5-year survival rate was 78.5 percent in the FEC-P arm and 72.1 percent in the FEC arm. There was a trend toward improved overall survival, but it did not reach statistical significance. "Because distant relapse-free survival is usually associated with overall survival, a statistically significant benefit in overall survival may become evident with a more protracted follow-up," the authors write.

A retrospective analysis of the data failed to detect a subgroup of patients who were more likely to respond to taxane therapy on the basis of their tumor's expression of the estrogen receptor and HER2.

In an accompanying editorial, Clifford Hudis, M.D., and Chau Dang, M.D., of Memorial Sloan-Kettering Cancer Center in New York review several trials that tested the potential benefit of adding taxanes to existing adjuvant therapy. From that point of view, the study by Martín and colleagues is important because it is well designed and uses a good regimen and schedule of drugs.

They emphasize that retrospective analyses should be considered hypothesis generating only, particularly when the results from several similar analyses are inconsistent "If you accept that the taxanes are effective, hormone receptor and HER2 status should not routinely guide your selection of patients for this therapy," the editorialists conclude.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Miguel Martín , Álvaro Rodríguez-Lescure , Amparo Ruiz , Emilio Alba , Lourdes Calvo , Manuel Ruiz-Borrego , Blanca Munárriz , César A. Rodríguez , Carmen Crespo , Enrique de Alava , José Antonio López García-Asenjo , María Dolores Guitián , Sergio Almenar , Jesús Fernando González-Palacios , Francisco Vera , José Palacios , Manuel Ramos , Jose Manuel Gracia Marco , Ana Lluch , Isabel Alvarez , Miguel Angel Seguí , José Ignacio Mayordomo , Antonio Antón , José Manuel Baena , Arrate Plazaola , Alfonso Modolell , Amadeu Pelegrí , Jose Ramón Mel , Enrique Aranda , Encarna Adrover , José Valero Álvarez , José Luis García Puche , Pedro Sánchez-Rovira , Sonia Gonzalez , José Manuel López-Vega , and On behalf of the GEICAM 9906 Study Investigators Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer Journal of the National Cancer Institute Advance Access published on May 27, 2008, DOI 10.1093/jnci/djn151.

Cite This Page:

Journal of the National Cancer Institute. "Addition of Paclitaxel to Standard Chemotherapy Improves Outcome in Early Breast Cancer." ScienceDaily. ScienceDaily, 27 May 2008. <www.sciencedaily.com/releases/2008/05/080527193157.htm>.
Journal of the National Cancer Institute. (2008, May 27). Addition of Paclitaxel to Standard Chemotherapy Improves Outcome in Early Breast Cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2008/05/080527193157.htm
Journal of the National Cancer Institute. "Addition of Paclitaxel to Standard Chemotherapy Improves Outcome in Early Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/05/080527193157.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins